Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2008-03-11
2008-03-11
Zeman, Robert A. (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S388600, C530S300000, C536S023200, C536S024200, C424S184100
Reexamination Certificate
active
07342101
ABSTRACT:
Disclosed are protein and peptide antigen and DNA compositions effective in generating immune responses against the pathogenic fungiCoccidioidesspp., the causative agents of coccidioidomycosis and Valley Fever. The invention thus provides protein and peptide antigens, DNA constructs, combinations and related biological compositions, and prophylactic and therapeutic methods of using such components and combinations to generate effective and protective immune responses againstCoccidioidesspp., includingC. immitis.
REFERENCES:
patent: 5284747 (1994-02-01), Milliman
patent: 5622827 (1997-04-01), McAllister et al.
patent: 5703057 (1997-12-01), Johnston et al.
patent: 5837734 (1998-11-01), Bartsch et al.
patent: 5989553 (1999-11-01), Johnston et al.
patent: 2003/0219455 (2003-11-01), Cole et al.
patent: 2003/0224013 (2003-12-01), Cole et al.
patent: 2004/0001843 (2004-01-01), Galgianìet al.
patent: 2004/0181046 (2004-09-01), Cole et al.
Cox et al (Valley Fever Vaccine Development, a progress report for Jul. 2002 through Dec. 30, 2002, Meeting held on Dec. 1, 2002).
Ivey et al (Identification of a protective antigen ofCoccidioides immitisby expression library immunization, Vaccine, Oct. 1, 2003; 21(27-30): 4359-4367).
Peng et al (Localization within a proline-rich antigen (Ag2/PRA) of protective antigenicity against infectionCoccidioides immitisin mice, Infection and Immunity, 2002; 70(7): 3330-3335).
Kirkland et al (Evaluation of the Proline-rich antigen ofCoccidioides immitisas a vaccine candidate in mice, Infection and Immunity, 1998; 66(8): 3519-3522).
Abuodeh et al., “Resistance toCoccidioides Immitisin Mice after Immunization with Recombinant Protein or a DNA Vaccine of a Proline-Rich Antigen,”Infect. Immun., 67(6):2935,2940, 1999.
Ampel et al., “In vitro Assessment of Cellular Immunity in Human Coccidioidomycosis: Relationship Between Dermal Hypersensitivity, Lymphocyte Transformation, and Lymphocyte Production by Peripheral Blood Mononuclear Cells from Healthy Adults,”J. Infect. Dis., 165:710-715, 1992.
Barry et al., “Protection Against Mycoplasma Infection Using Expression-Library Immunization”,Nature, 377(6550):632-635, 1995.
Billetta et al., “A Novel Antigen fromCoccidioides ImmitrisIdentified by Expression Library Immunization (ELI),”Immunol. Letts., 73(2-3):269, 2000, Abstract = 794.
Billetta et al., “Identification of a Novel Antigen fromCoccidiodes ImmitisUsing Immuno-Based Functional Genomic Methods,”The Midwinter Conference of Immunologists, Jan. 22-25, 2000.
Burgess et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-Binding Activites by Site-Directed Mutagenesis of a Single Lysine Residue,”J. Cell Biol., 111:2129-2138, 1990.
Corry et al., “Cytokine Production by Peripheral Blood Monouclear Cells in HumanCoccidiodomycosis,”J. Infect. Dis., 174:440-443, 1996.
Cox and Magee, “Coccidiodomycosis: Host Response and Vaccine Development,”Clin. Microbiol. Rev., 17(4):804-839, 2004.
Cox et al., “Valley Fever Vaccine Development,” Progress Report submitted to California State Bakersfield Foundation, Valley Fever Vaccine Project Meeting, Report for Period Jul. 2002-Dec. 30, 2002. Meeting held Dec. 1, 2002.
Cox and Magee, “Vaccine Efficacy ofCoccidioides ImmitisAntigen 2,” Progress Report submitted to California State Bakersfield Foundation, Valley Fever Vaccine Project Meeting, Report for Period Jul. 1, 2000-Dec. 31, 2000. Meeting held Dec. 4-5, 2000.
Cox and Magee, “Vaccine Efficacy ofCoccidioides ImmitisAntigen 2,” Progress Report submitted to California State Bakersfield Foundation, Valley Fever Vaccine Project Meeting, Report for Period Jan. 1, 1998-Dec. 31, 1999. Meeting held Feb. 22-23, 2000.
Cox and Magee, “Vaccine Efficacy ofCoccidioides ImmitisAntigen 2,” Progress Report submitted to California State Bakersfield Foundation, Valley Fever Vaccine Project Meeting, Report for Period Jan. 1, 2000-Jun. 31, 2000. Meeting held Jun. 13-14, 2000.
Cox and Magee, U.S. Appl. No. 60/178,571; Entitled “Use of DNA and Expressed Protein as a Vaccine Against Coccidioidomycosis”; by Rebecca A. Cox and D. Mitchell Magee; filed Jan. 28, 2000.
Cox and Magee, “Protective Immunity inCoccidioidomycosis,” Res. Immunology, 149:417-428, 1998.
Delgado et al., “A Recombinant β-1,3-Glucanosyltransferase Homolog ofCoccidioides posadasiiProtects Mice againstCoccidioidomycosis,” Infect. Immunol., 71(6):3010-3019, 2003.
Dolan and Cox, “Production and Characterization of a Monoclonal Antibody to the Complement Fixation Antigen ofCoccidioides Immitis,” Infect. Immun., 59(6):2175-2180, 1991.
Dugger et al., “Cloning and Sequence Analysis of the cDNA for a Protein fromCoccidioides Immitiswith Immunogenic Potential,”Biochem. Biophys. Res. Comm., 218:485-489, 1996.
Franco et al., “An Immunodominant Cytotoxic T Cell Epitope on the VP7 Rotavirus Protein Overlaps the H2 Signal Peptide,”J. Gen. Virol., 74:2579-2586, 1993.
Hombach et al., “Strictly Transporter of Antigen Presentation (TAP)-Dependent Presentation of an Immunodominant Cytotoxic T Lymphocyte Epitope in the Signal Sequence of a Virus Protein,”J. Exp. Med., 182:1615-1619, 1995.
Ivey et al., “Identification of a Protective Antigen ofCoccidioides Immitisby Expression Library Immunization,”Vaccine, 21:4359-4367, 2003.
Jiang et al., “Genetic Vaccination AgainstCoccidioides Immitis: Comparison of Vaccine Efficacy of Recombinant Antigen 2 and Antigen 2 cDNA,”Infect. Immun., 67(2):630-635, 1999.
Jiang et al., “Coadministration of Interleukin 12 Expression Vector with Antigen 2 cDNA Enhances Induction of Protective Immunity AgainstCoccidioides Immitis,” 67(11):5848-5853, 1999.
Jobling and Holmes,“Analysis of Structure and Function of the B Subunit of Cholera Toxin by the Use of Site-Directed Mutagenesis,”Mol. Microbiol., 5:1755-67, 1991.
Kirkland et al., “Evaluation of the Proline-Rich Antigen ofCoccidioides Immitisas a Vaccine Candidate in Mice,”Infect. Immun., 66(8):3519-3522, 1998.
Kondo et al., “A Single Retroviral Gag Precursor Single Peptide Recognized by FBL-3 Tumor-Specific Cytotoxic T. Lymphocytes,”J. Virol., 69(11):6735-6741, 1995.
Lazar et al.,“Transforming Growth Factor α Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Mol. Cell Biol., 8(3):1247-1252, 1988.
Li et al., “Recombinant Urease and Urease DNA ofCoccidioidomycosis ImmitisElicit and Immunoproteactive Response AgainstCoccidiodomycosisin Mice,”Infect Immun., 69(5):2878-87, 2001.
Magee, Presented theCi-ELI-AGl Data at the 15thCongress of the International Scoiety for Human and Animal Mycology, San Antonio, Texas, May 25-29, 2003.
Pan and Cole, “Molecular and Biochemical Characterization of aCoccidioides Immitis-Specific Antigen,”Infect. Immun., 63(10):3994-4002, 1995.
Rudinger, “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence,” In ‘Peptide Hormones’, edited by Parsons, J.A., University Park Press, Jun. 1976, p. 6.
Stevens, “Current Concepts:Coccidioidomycosis,” N. Eng. J. Med., 332:1077-1082, 1995.
Yu et al., “Isolation and Characterization of the Urease Gene (URE) from the Pathogenic Fungus,Coccidioides Immitis,” Gene, 198(1-2):387-91, 1997.
Zhu et al., “Identification of aCoccidioides ImmitisAntigen 2 Domain That Expresses B-Cell Reactive Epitopes,”Infect. Immun., 65(8):3376-3380, 1997.
Zhu et al., “Coccidioides ImmitisAntigen 2: Analysis of Gene and Protein,”Gene, 181:121-125, 1996.
Zhu et al., “Molecular Cloning and Characterization ofCoccidioides ImmitisAntigen 2 cDNA,”Infect. Immun., 64(7):2695-2699, 1996.
Accession No. U
Cox Rebecca A.
Ivey F. Douglas
Magee D. Mitchell
Woitaske Melanie D.
Myers Bigel Sibley & Sajovec P.A.
The University of Texas System & Board of Regents
Tongue Lakia J
Zeman Robert A.
LandOfFree
Compositions and methods comprising a protective antigen of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods comprising a protective antigen of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods comprising a protective antigen of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2799585